REDWOOD CITY, Calif., Oct. 7, 2025 — Precision NeuroMed (PNM), a clinical-stage biotechnology company advancing next-generation drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its investigational therapy cintredekin besudotox (IL13-PE38QQR) for the treatment of glioblastoma multiforme (GBM) — one of the most aggressive and deadly forms of brain cancer.
Science SignificanceAVB-114
Glioblastoma remains a formidable challenge in oncology, with a median survival of just 12 to 18 months and a five-year survival rate near 5%. Despite major genomic insights, progress has been stalled by the blood–brain barrier (BBB) — a physiological defense that blocks most systemically delivered therapeutics. Precision NeuroMed’s proprietary convection-enhanced delivery (CED) platform provides a potential solution. The technology uses continuous, pressurized microinfusion to bypass the BBB and deliver biologics, nanoparticles, or gene therapies directly into tumor-infiltrated regions of the brain. Cintredekin besudotox, a recombinant cytotoxic fusion protein, binds to IL-13 alpha-2 receptor (IL13aR) — a receptor highly expressed on GBM cells but largely absent on normal brain tissue. This molecular targeting enables precision destruction of tumor cells with minimal off-target neurotoxicity. According to CEO and Co-Founder Dr. Sandeep Kunwar, “Combining a selective biologic with our next-generation delivery system gives us a way to reach and treat brain cancer regions that conventional therapies can’t access.”
Regulatory Significance
The FDA’s Orphan Drug Designation affirms both the unmet need and therapeutic potential of cintredekin besudotox. This designation provides seven years of market exclusivity upon approval, tax credits for qualified clinical research, and waivers for certain FDA fees. More importantly, the ODD status streamlines interactions with the FDA, de-risking early-stage development and potentially enabling priority review or fast-track pathways in subsequent regulatory submissions. From a compliance perspective, PNM’s CED technology aligns with FDA’s evolving framework for drug–device combination products, particularly those delivering macromolecules directly into the CNS. This regulatory alignment could help establish new standards for intracerebral drug delivery validation and quality assurance under cGxP conditions.
Business Significance
Advertisement
For Precision NeuroMed, the Orphan Drug milestone represents a strategic inflection point in its mission to transform neuro-oncology treatment. The company is now positioned to expand partnerships, secure investor confidence, and accelerate its clinical and translational roadmap for both GBM and other CNS disorders. The global glioblastoma treatment market — estimated at over $2.5 billion by 2028 — remains dominated by surgery, radiation, and temozolomide-based chemotherapy. With no new frontline therapeutic approved in nearly two decades, PNM’s platform offers an opportunity to disrupt an under-innovated sector with a targeted, delivery-enabled biologic. The company’s long-term business strategy is to apply its CED platform to a portfolio of CNS diseases, including metastatic brain tumors, neurodegenerative conditions, and gene therapy administration. This model integrates precision biologics with specialized hardware, potentially creating repeatable, device-enabled revenue streams within the neuro-therapeutics ecosystem.
Patients’ Significance
For patients diagnosed with glioblastoma, this announcement signals renewed scientific hope. Current treatments—surgery, radiation, and temozolomide—have remained largely unchanged since 2005, offering limited efficacy and substantial side effects. PNM’s targeted approach aims to extend survival and improve neurological outcomes by reaching tumor cells beyond the surgical margin, a key driver of relapse. The direct infusion of cintredekin besudotox through the company’s CED system allows clinicians to maintain high local drug concentrations in diseased tissue while minimizing systemic exposure. This therapeutic precision aligns with modern neuro-oncology’s goal: not only to extend life but also to preserve cognitive and functional quality of life. If successful, PNM’s therapy could mark the beginning of a new era of localized, disease-modifying treatment for brain cancer.
Policy Significance
The FDA’s decision reinforces the policy intent behind the Orphan Drug Act, encouraging innovation in rare and high-risk disease areas that lack commercial incentives. Glioblastoma, affecting fewer than 200,000 Americans annually, represents a textbook example of the “orphan disease gap” — where scientific feasibility often outpaces financial viability. By granting ODD to Precision Neuromed, the FDA is not only validating the company’s approach but also supporting a broader policy shift toward enabling breakthrough CNS therapies. PNM’s program aligns with federal initiatives that prioritize neurotherapeutic innovation, precision delivery technologies, and small biotech-driven R&D pipelines. The case could also inform future regulatory policies on combination device–biologic approvals in CNS applications, a growing frontier where safety validation, local biodistribution, and data integrity require new evaluative frameworks.
Transaction Highlights
Precision NeuroMed has been granted FDA Orphan Drug Designation for cintredekin besudotox (IL13-PE38QQR) in glioblastoma multiforme (GBM), marking a major milestone in its CNS oncology portfolio. The designation recognizes the therapy’s potential to address an area of profound unmet medical need while providing regulatory incentives including market exclusivity, tax benefits, and fee exemptions. The therapy leverages PNM’s proprietary convection-enhanced delivery (CED) platform, which enables direct, localized administration of therapeutics into the brain, bypassing the blood–brain barrier. Cintredekin besudotox selectively targets the IL-13 alpha-2 receptor, allowing molecularly precise tumor destruction with minimized impact on normal tissue. With the Orphan Drug status now secured, Precision NeuroMed intends to advance the program into further clinical development, explore partnerships to expand the CED platform, and broaden its pipeline across CNS and neuro-oncology applications. This achievement reinforces PNM’s leadership in precision neuromedicine, integrating biologics and delivery innovation to improve outcomes in devastating brain diseases.
Source: Precision NeuroMed Press Release
